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The surgical fields have always piqued an interest in me and thus have driven a significant 
part of my academic efforts. Gastroenterological surgery, being one of the major surgical 
specialties has brought me both frustration and joy. Complex and life-saving procedures, 
being at the front lines of both elective and emergency surgery world-wide.  
Cancer being a major cause of death, is no exception to the daily objectives of a GI-surgical 
team.  
 
The purpose of this study was to determine whether the introduction of a minimally 
invasive, more modern technique would lead to improvement for patients with gastric 
adenocarcinoma.  
 
The question raised in this study was primarily directed at survival and post-operative 
complications between the two different surgical approaches. It was also interesting to 
determine if the degree of resection made a difference, as well as the time periods 
themselves.  
 
My undivided gratitude and many thanks to my mentor Eirik Kjus Aahlin, for sharing his 
valuable time. Between being a consultant GI-surgeon and spending his few vacant hours 
with his family, he has guided me through the complexity of the field. Had it not been for his 
expertise on the subject, one would drown in the ocean of information and surely struggle.  
 
As a final addendum to the preface I would like to thank the sensors for reading my thesis 
carefully and critically during the first evaluation. The work of pointing out both the qualities 
and especially the areas in need of improvement, has not gone unnoticed. I have made 
effort to refine my work and undoubtedly profited by learning even more about the topic. 
 31.10.2020              Tromsø 
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Background: Gastric cancer is one of the leading causes of cancer related death, world-wide. 
The most common type is adenocarcinoma, which account for 95% of all gastric tube 
cancers. Curative treatment always includes surgery and, with few exceptions, neoadjuvant 
and adjuvant chemotherapy. The surgical treatment of gastric cancer has changed from 
open to minimally invasive surgery in many centers around the world. Minimal invasive 
surgery has been associated with decreased length of stay and fewer complications 
compared to open surgery.  
Our study aimed to investigate whether the introduction of minimally invasive gastrectomy 
for adenocarcinoma in the gastric tube was associated with similar benefits, as well as better 
survival rates at the University hospital of Northern Norway. 
 
Methods: Minimal invasive gastric cancer surgery was introduced at the University Hospital 
of Northern Norway in 2012. 170 patients admitted for curative treatment of gastric 
adenocarcinoma, with either minimally invasive surgery or open surgery, in the period of 
2007 to 2017 were included and studied retrospectively using SPSS 26 (IBM). 
 
Results: Statistical analysis did not show a significant difference in survival using minimally 
invasive surgery compared to open surgery (p=0.45), nor a significant difference in survival 
between the two time periods (p=0.50).  There was however a significant association 
between minimally invasive surgery and a decreased length of stay (p=0.009). Subtotal 
gastrectomy was associated with decreased length of stay (LOS) compared to total 
gastrectomy (Average LOS 8 vs. 13 days, p=0.005). There was no significant difference in 
severe complications between open and minimal invasive surgery (p=0.12), but significantly 
fewer severe complications were observed in the 2012-2017 period (p=0.007). 
 
Conclusion: This study does not show increased survival, nor a reduction in postoperative 
complications using minimally invasive surgery to treat gastric adenocarcinoma, compared 
to open surgery. A significant reduction in length of stay and postoperative complications 
was observed in the recent years. Some of this might be associated with the introduction of 







Gastric cancer is a malignant disease with decreasing incidence worldwide and especially in 
Europe and North America. The prognosis is gradually improving, yet poor compared to 
colorectal cancer. In 2012, Gastric cancer was the fifth most prevalent cancer, and the third 
leading cause of cancer-related death (1). 
 
There are many risk factors for developing gastric cancer. One of the significant risk factors 
for gastric cancer is Helicobacter Pylori. Eradication of this bacteria is known to reduce the 
risk of developing gastric neoplasms, but even after eradication patients can develop gastric 
cancer (2). The decreasing prevalence of Helicobacter Pylori around the world is thought to 
be one of the reasons for the astonishing global decrease in gastric cancer. Mapping out the 
risk factors in a population where Helicobacter Pylori is far less prevalent is a complex task, 
but necessary to further reduce incidence.  Thus, identifying modifiable risk factors is a key 
part in the prevention of gastric cancer. The reduction in salt-preservation of foods and the 
introduction of the electrically cooled refrigerator and freezer is discussed as partly 
responsible for reducing the incidence in the west (3). Although the northernmost region in 
Norway have had access to modern kitchen appliances for decades, a cultural culinary 
heritage, with salt as a preservative for both fish and meat, still yields a high salt intake. 
Another challenge is that  the region has for a long time been  on the top of national 
statistics on tobacco-use and alcohol consumption (4).  Convincing data from Buckland et al., 
with results from the EPIC-cohort, showed that nearly 20% of all gastric cancer could be 
prevented if the participants had followed the healthy life style behaviors of their index (5). 
Buckland described non-smoking, no/low-alcohol consumption and adherence to the 
Mediterranean diet as key constructs in reducing chance of gastric cancer. The revised 
Mediterranean diet score coarsely consists of tertile scores 1-3 based on intake of fruit, 
vegetables, fresh fish and olive oil, as well as few other variables (6). 
 
When preventative measures have come too short, and cancer has developed; the prognosis 
of gastric cancer is poor. In the period 2011-2015 the five-year relative survival rates in 
Norway were only 24.3% and 24.6% in men and women, respectively (7). The latest 




survival; 27.8% in men and 26.7% in women (8). There are multiple modifiable and 
unmodifiable disease related factors associated with a worsened outcome. Examples being 
male gender, high age, cancer in an advanced stage, the lack of adherence to chemotherapy 
and major treatment related complications (9-15). 
 
Another unmodifiable risk factor for developing gastric cancer is heritage and familial gastric 
cancers. The diseases are rare, but about 1-3% of gastric cancers are of the hereditary 
diffuse gastric cancer type with mutation in the tumor suppressor gene CDH1 (16). There are 
several other genes related to the development of gastrointestinal cancer, gastric cancer 
included (17). Gene-analysis is recommended if the patient is diagnosed with a diffuse 
stomach cancer before the age of 40 or there is a familial pattern, as well as annual 
screening in high risk population (16). 
 
Minimally invasive surgery (MIS) is in general known to cause less post-operative immune 
suppression, shorter hospital stay and less pain (11). Complications both perioperatively and 
postoperatively along with prolonged hospital stays are in turn associated with worsened 
outcomes and increased mortality and morbidity (7, 18, 19). This is true for most types of 
surgical intervention, including gastric cancer (5). 
 
There is a difference in incidence between the west and the east (20). Eastern countries 
have a higher incidence, thus a vast number of strong studies come from the Asian 
countries. Large randomized controlled trials (RCTs) from Asia have previously documented 
the non-inferiority of MIS when compared to open surgery. The Korean laparoendoscopic 
gastrointestinal surgery study (KLASS) with authors Kim, Kim, and Han et. al. published a 
phase 3 multicenter study in 2016, comparing laparoscopy-assisted distal gastrectomy 
(LADG) to open distal gastrectomy (ODG). The authors conclude that LADG is safe, and has 
the benefit of fewer wound complications compared to ODG (21). A year later a publication 
by the Japanese Clinical Oncology Group (JCOG) concluded that LADG was non-inferior 
compared to ODG regarding adverse events and short time survival.  In the conclusion, they 
also stated the need for studies proving that the relapse free survival is better or non-
inferior (22) with LADG in order to consider it an alternative to ODG. A recent study from the 




Association (JAMA) by authors Yu, Huang, Sun et al. has relapse as a secondary outcome. 
The CLASS-01 study concludes that open surgery and MIS was equally safe and that there 
was no significant difference in recurrence between the two arms (23). 
 
Prior to the fifth edition (2018) of the Norwegian national guidelines (NGICG), there were no 
recommendation of minimally invasive versus open surgery. The department of 
gastrointestinal surgery at the University Hospital of Northern Norway (UNN) introduced a 
change in surgical modality in 2012.  Going from open surgery to minimally invasive surgery, 
when possible. 
 
Gastrectomies were complimented with resection of at least 16 lymph nodes, using a 
modified D2-resection, in accordance with national guidelines since the first edition. A 
modified D2 is described in the nation guidelines as an extended lymph node dissection, 
entailing removal of nodes in station 1 to 12a, except for station 10 and without the removal 
of spleen and pancreas. The level of evidence to support this choice of lymph node resection 
changed from grade D (low level) in the first four editions, to grade A (high level) in the fifth 
and most recent guideline(16).  
 
The MAGIC study from 2006 influenced the preferred oncological treatment of resectable 
gastric cancer in Norway. Perioperative chemotherapy with epirubicin, cisplatin and 5-FU 
(ECF) was inaugurated for stages II to III in 2007 as a result of the study. The study itself has 
been criticized, and several studies have shown a lack of long term benefit of the 
aforementioned chemotherapy-treatment (24, 25). The choice of chemotherapy has more 
recently been modified, with the FLOT-study by Al-Batran et. al. showing improved results 





Tumor, node, and metastasis 
The Tumor-node-metastasis (TNM) classification is a method of categorizing neoplasms 





Tis, the least invasive tumor category, only involves the epithelium - above the lamina 
propria. This T-status never constitutes advanced cancer and is along with T1 (without lymph 
node involvement or metastasis) the tumor stage with the highest survival rate (27). 
T1 is characterized by infiltration through the lamina propria or through the submucosa. 
As the tumor progresses further and breaches through the muscularis propria or the 
subserosa it develops into T2. T3 involves the visceral peritoneum, but not further. As it 
invades deeper and involves organs and structures outside the serosa (visceral peritoneum) 
it is called T4; the highest T-status. 
 
Lymph node involvement is determined by resection of at least 15 nodes surrounding the 
stomach and includes microscope examination of the nodes to evaluate the spread of tumor 
cells. The more lymph nodes that are affected, the higher the N-status becomes. N0 - zero 
lymph nodes, N1 involves 1-6 nodes. N2 is 7-15 and all above 15 is N3. 
 
Metastasis is a dichotomized category with a M0 for no metastasis and M1 for confirmed 
distant metastasis. 
 
Staging is a result of these three variables, as shown in Table 1. Higher stage involves a 
worsened prognosis (27). 
 
Another term frequently used is early gastric cancer (EGC) and is defined by Murakami as 




The Siewert classification is a classification system based on the anatomical location of a 
tumor in the junction between the esophagus and the stomach (figure 3). This area is called 
the gastro-esophageal junction or the esophago-gastric junction (GEJ/EGJ) in the literature 
and is based upon the area proximal and distal to the anatomical cardia. (16).  
 




Type II – tumor center is located between 1 cm proximal and 2 cm distal to the anatomical 
cardia. Type III – Tumor center is located between 2 and 5 cm distal to the anatomical cardia. 
 
Clavien-dindo 
The Clavien-dindo (CD) classification system for postoperative complications is considered a 
reliable tool for classifying complications in surgery regardless of borders and specialty (29). 
The classification system was developed to report complications in a similar manner across 
the world and different fields of surgery. The Clavien-Dindo group proposed a system that 
focuses on the level of treatment necessary to correct the complication. 
 
The lowest grade (Grade I) of complication is defined as any deviation from the 
postoperative course, without the need for intervention. Grade II is defined as 
pharmacological treatment with drugs, blood transfusion and total parenteral nutrition. 
Grade III is surgical, endoscopic, or radiological intervention, and is divided into two separate 
subgroups depending on the need for general anesthesia or not. Grade IV is a life-
threatening organ dysfunction/complication requiring intensive care management. This 
grade is also divided in two subgroups, depending on it being a single organ dysfunction or 
multiorgan dysfunction. Grade V is postoperative death. 
 
The main objectives of this thesis were to analyze gastric cancer surgery at the University 
Hospital of Northern Norway, in a decade (2007-2017) when both perioperative 
chemotherapy and minimally invasive surgery were introduced. This in order to evaluate the 
efficacy of the new technique and most importantly determine if it is as safe as the open 
approach. Furthermore, we aimed to compare two patient cohorts: The period with mainly 
open surgery, 2007-2011, with the period with mainly minimally invasive surgery, 2012-








A total of 212 patients which underwent surgery for gastric cancer between March 2007 and 
December 2017 at the University hospital of Northern Norway (UNN) were included. 
Inclusion criteria were curative surgery for gastric cancer (adenocarcinoma) performed in 
the period 2007-2017 at UNN. 170 of the 212 resected tumors were adenocarcinoma, the 
remaining 42 being mostly neuroendocrine tumors (NET) and gastrointestinal stromal 
tumors (GIST) and thus excluded from the study. Thus, 170 adenocarcinoma gastric cancers 
were included in the study. 
 
Our study is a retrospective cohort study, based on information gathered from electronic 
patient journal (EPJ) from a single center (UNN). Registration of death was done using 
passive follow-up in January of 2020, making the shortest follow up time two years. 
 
The collected data was entered in a dataset and all data was collected through DIPS 
electronic patient journal (EPJ). The thesis protocol was presented to the hospital’s PVO 
(Data protection officer at UNN) 16.10.18 through their internal reporting system. 
 
Groups 
Operative strategy for gastric cancer at UNN was determined according to tumor location 
and depth of invasion and were based on current recommendations from the Norwegian 
guidelines. Patients with gastric cancer should be evaluated and treatment planned by a 
multidisciplinary team consisting of radiologist, surgeon, oncologist, gastroenterologist and 
preferably a pathologist (16, 30-33). 
 
Patients were dichotomized into male vs. female, elderly (≥60 years) vs. younger, open vs. 
minimal invasive surgery (MIS), total vs. subtotal gastrectomy, neoadjuvant chemotherapy 
vs. direct surgery, adjuvant vs. no adjuvant chemotherapy, Clavien-Dindo ≥ 3a vs. Clavien-





Ordinal variables, such as clinical stage, pathological stage, number of lymph nodes were 
also gathered. As well as other cancer specific variables, like histological classification. 
 
Analysis 
Statistical analyses were performed using SPSS version 26.0 (SPSS Inc, Chicago, IL). 
Variables were grouped into: Preoperative clinic, Surgical factors, complications, pathology 
studies, chemotherapy, metastases, and survival (table 2). 
 
Statistical significance is defined as a p-value of 5% (0.05) or lower. 
 
Descriptive analyses were performed using mean and median. Normality was tested using 
the Kolmogorov-Smirnov test. 
 
Median survival to describe survival time was chosen. Distribution of survival time is often 
skewed to the right, because a large proportion of patients die relatively soon after 
diagnosis, whereas some survive for much longer. The median may thus present a more 
accurate estimate of survival time than mean. 
 
Absolute frequencies (n) and the relative frequencies (%) were studied where relevant. 17 
variables were grouped to non-modifiable factors, treatment related factors, complications 
and pathological factors as shown in tables 1 to 4. 
 
Independent T-test was used to compare independent and normally distributed samples 
from the studied binominal variables.  Mann-Whitney U test was applied where there was a 
small sample (n<50) and non-gaussian distribution (17). General linear model was used to 
adjust for covariates in univariate measurements. 
 
Fischer exact test was used to measure difference between two unpaired groups with a 
binominal outcome (death within 1-year, major complication e.g.).  Spearman correlation 





Kaplan-Meier was used as a descriptive survival analysis of all patients, as well as 
comparative between groups. Mantel-Cox/Log-rank was used to measure whether there 
was a significant difference in survival. 
 
Simple linear regression was used to predict value from another measured variable. 






In the period 2007-2017, 170 patients underwent resection for gastric adenocarcinomas at 
the University Hospital of Northern Norway. Distribution of gender was approximately 2:1 
with 111 male patients (65%) and 59 female patients (35%) (table 3). The mean age for all 
patients were 69 years (35-88), with no difference between genders (p=0.54). 
 
More patients were treated after 2011, with 95 cases in the 2012-2017 period (56%) vs. 75 
resections between 2007 and 2011 (44%). 
 
Surgical factors 
Surgical approach in this study was categorized into laparotomy or laparoscopy. In total 170 
resections were included and 101 (59%) were planned laparotomies. Of the 69 performed 
laparoscopies, a total of 16 (23%) were converted to open. Thus, the total number of 
laparoscopic gastrectomies were 53 (table 4). There was no statistically significant difference 
in TNM stage between the open vs. MIS group (p=0.94). 
 
Type of resection was grouped into total and subtotal gastric resection in this study. 104 
(61%) resections were categorized as a total resection. There was no statistically significant 





Cancer stage and histology 
The most prevalent stages were 2a and 2b (19% and 19%) using pathological TNM (pTNM) 
and staging. Most tumors affected the sub-serosa or deeper (T>2 = 55%). Signet ring cell 
carcinoma, which is considered a highly malignant subtype, was found in 32 (19%) of the 
resected specimens (table 6). There was no statistically significant difference stage between 
the signet vs no-signet group (p=0.30). 84 (49%) patients had no lymph node involvement on 
pathological examination. 156 (92%) had no metastasis on examination. 
 
Chemotherapy 
Approximately half of the population received neoadjuvant chemotherapy (49%) and about 
two fifths (41%) received adjuvant chemotherapy.  There was significant difference between 
pathological stage for those who received neoadjuvant and those who did not (p=0.018). 
Those with advanced stage cancer received perioperative chemotherapy more often. There 




Severe complications, categorized in this study as Clavien-Dindo (CD) greater than or equal 
to 3a, occurred in 42 (25%) patients (table 7). 
 
Postoperative complications and length of stay 
There was no significant difference in complication rates between the total vs. subtotal 
group (p=0.12) or the open vs. laparoscopic group (p=0.12). There was no change in 
significance when adjusted for age and gender using logistic regression. However, the period 
cohorts had a significant difference in the amount of severe complications with 26 cases in 
the first period vs. 16 in the later years (p=0.007). 
 
Hospital stay was shortened from ≈13 days in the open group to ≈7 days in the MIS group 
(p=0.009).  Similar results were shown with type of resection, subtotal gastrectomy had ≈8 
days and total gastrectomy had ≈13 days on average (p=0.005). Length of stay also changed 






Anastomotic leak occurred in 16 patients (9%). There was no significant difference between 
the two surgical methods (p=0.43) or between the two time periods (p=0.98). 
 
90-day mortality 
A total of 5 patients died within the first month. 30-day mortality was ≈3%. Within the next 
60 days; 2 more patients succumbed, giving a 90-day mortality of 4% (table 7). Cumulative 
90-day survival is 96% in our population. In the period 2007-2011 93% survived, while in 
2012-2017 there was a 98% survival. There was no significant difference between the 
periods (p=0.14). 
 
Death within 1 year 
31 patients (18%) died within one year. There was no significant difference in one-year 
mortality between the time periods (p=0.09) or open vs minimal invasive resection (p=0.07). 
There was however a significant association between subtotal vs. total gastrectomy and 
death within one year (p=0.004). There were fewer cases of death within one year in the 
subtotal-group (5 vs. 26). 
 
Survival analysis 
Actual 1-year survival for the entire population was 82% and estimated 5-year survival was 
44% (Figure 4). Median survival for all groups was 3 years and 11 months. 
 
Minimally invasive surgery vs. open surgery 
MIS had a median survival time of 4 years and 4 months, and open surgery had 3 years and 2 
weeks. The difference was not statistically significant (p=0.45). 1- and 5-year survival for MIS 
was 88% and 49%, respectively. Open surgery had 79% and 41%, respectively (Figure 5). 
 
Total vs. subtotal gastrectomy 
Total gastrectomy had a median survival time of 2 and a half years. While the subtotal group 




(p=0.012). After five years the total resection group had 38% survival, while the sub-total 




In the 2007-2011 cohort the median survival time was just short of 3 years. The 2012-2017 
cohort on the other hand had approximately 4 years and 4 months.  There was however no 
significant difference (p=0.50). After five years the 2007-2011 cohort had 41% survival, while 






During these ten years of Gastric cancer treatment at the University Hospital of Northern 
Norway there were 170 gastrectomies due to adenocarcinoma of the gastric tube. The goal 
of studying the implementation of a new surgical modality is to evaluate potential benefits 
of the new technique and equally important check for potential inferior results. MIS has 
become an important supplement to the modern surgical approach. MIS was significantly 
associated with decreased length of stay, but there was no statistically significant difference 
in severe complications or overall survival compared to open surgery in this study.  These 
results do not differ from the general consensus currently.  
 
Significantly shorter length of stay was observed after subtotal vs total gastrectomy. There 
was no significant difference in complications between subtotal and total gastrectomy. 
However, there was a difference in 5-year survival, survival after total gastrectomy was 
approximately 15% lower compared to subtotal gastrectomy (p=0.012). This might be 
indicative of several things. Gastroesophageal junction (GEJ) cancer is a known location for 
increasing incidence and a worse prognosis (34-36). A sub-total resection is the treatment of 
choice for distal-third and middle gastric cancer, as it provides similar rates of survival and 
better post-operative organ function. This is especially true in early stage disease (37). The 
use of subtotal resection is also related to a less advanced cancer (with less chance of micro-
metastases (38)) and a smaller tumor size. In our study there was no significant difference in 
pathological stage between the total gastrectomy and subtotal group. See figure 1 and 3 for 
tumor growth and distribution, as well as Table 1 for staging. 
 
Due to a higher incidence of gastric cancer in the east compared to the west, there has been 
an adoption of screening programs in countries like Japan and Korea. This allows for 
detection of early gastric cancer, and early surgical treatment. Cancer survival rates can be 
described as inversely proportional to cancer stage. Early gastric cancer has more than 90% 
five-year survival rate (39). One can theorize that this, at least in part, is a reason for the 
discrepancy between eastern and western survival.  It is not the complete truth as there are 
studies showing a difference in survival even when stratified by stage (40). The 
implementation of a similar national screening program with the relatively low incidence in 




annual screening with gastroscopy and multiple biopsies. Surveillance of hereditary gastric 
cancer is an example of this. Screening in hopes of early recognition and curative treatment 
might be the key to minimizing mortality and morbidity in patients with high risk for 
developing gastric cancer. 
 
Overall, 5-year survival in Norway is expected to be between 35-50% in curatively treated 
gastric cancer, with a tendency towards large volume centers having the highest survival (16, 
41). The numbers nationwide are slowly, but steadily improving.  In our study UNN had an 
estimated 5-year survival of 44%, regardless of surgical modality and other factors such as 
stage. An important consideration in the population is the potentially increased risk of 
advanced cancer. This due to reduced accessibility to specialist health care (42) combined 
with a high prevalence of modifiable risk factors. 
 
A total of 25% of treated patients had a severe complication. This is less than the national 
average of 28% in gastrectomies during the period 2016-2018, but it is considerably higher 
than optimal (43). Anastomotic leak was prevalent in 16 patients (9%). This is above the 
national treatment goal of <5% and the acceptable level of <8% (16, 43). There was no 
significant difference in anastomotic leak between the surgical techniques (p=0.43) or the 
time periods (p=0.98). Although complication rates are declining in the fields of surgery, 
increased operator experience, as well as more research on complication reducing factors 
and safe surgery should prompt better results for patients, as shown in several studies (44, 
45). 
 
2- year passive follow up/censor is an acceptable length of follow up, although actual five-
year survival would be preferable. 170 patients make for a good number of cases in total. 
Adjusted for different variables some analyses are prone to become weaker due to a small 
number of cases, and in some instances cause type II statistical error. Passive follow-up 
might give an overestimation of the true survival rate:  the error is due both to the reliability 
of the national registration process and to emigration of registered cases abroad. The results 
of this study are based on retrospective analyses, and therefore only associations. They are 






Outcome after treatment for  gastric cancer are steadily improving nationwide, both in 
terms of mortality and morbidity (41). At the University Hospital of Northern Norway there 
has been a similar pattern. In this study there was no statistically significant difference in 
survival, as well as no significant difference in frequency of complications, between open 
and minimally invasive technique. A significant reduction in length of stay was observed in 
the recent years. Although many factors are at play, some of this might be associated with 
the introduction of minimal invasive surgery. There was a trend towards better survival in 
the latest period, but the difference was not statistically significant. This might be caused by 
the small size of the cohort. Further research at the gastrointestinal surgical ward at UNN, 
with longer follow up and a larger study population, as well as continued efforts to maximize 
patient outcome is warranted. 
 
Ethics and disclosure 
The patient data has been collected after treatment and all patients received the procedural 
course of treatment for their time of admission.  The study has caused no change in 
treatment or outcome, on the contrary may be used to improve patient outcome in the 
future. 
 
The project had no need for an external budget. All software licenses are paid for by the 
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Figure 1: Tumor distribution and classification according to invasion through mucosal layers. 
Figure 2(47):  
  
Figure 2: Perigastric lymph nodes along the minor and major curvature, as well as lymph nodes along the 
arteries supplying and surrounding the stomach. The left image shows lymph nodes in the minor curvature (1) 
and the major curvature (2). The right image shows lymph nodes next to the left gastric artery (1), the common 










Figure 4:  Overall survival in the entire population 
 
Figure 4: This figure shows up to five-year survival for the entire population. 
 
 
Figure 5: Survival according to minimally invasive surgery (MIS) or open approach. 
 
Overall Comparisons 
 Chi-Square df Sig. 




Test of equality of survival distributions for the different levels of Surgical 
method. 
Figure 5: This figure shows survival according to the two surgical methods, open vs. 
minimally invasive surgery. There was no statistically significant difference between 
the arms (p=0.45).   
 




 Chi-Square Df Sig. 
Log Rank (Mantel-Cox) 6,299 1 ,012 
Test of equality of survival distributions for the different levels of 
Resection. 
 
Figure 6: This figure shows survival according to grade of resection total vs. subtotal. There was a statistically significant 
difference in survival between the two resection types (p=0.012).   
 










Figure 7: This figure shows survival according to time periods the surgery took place. There was no statistically significant 
difference in survival between the time-periods (p=0,50).  
  
Overall Comparisons 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox) ,449 1 ,503 






Table 1: Tumor-Node-Metastasis (TNM) classification for determining cancer stage (49) 
 
 Stage 1 





Table 2: This table shows the variable list used for collecting data prior to analysis.  
 
  
Table 2: All included variables 
Patient related factors • Gender 
• Age 
• Time period 
Preoperative clinic - Preoperative histology 
- Preoperative CT; cTNM 
Surgical 1. Resection type 
a. Subtotal 
b. Total 
2. Surgical approach 
a. Minimally invasive 
b. Open 
Complications - Severe complication (Clavien-Dindo > 3) 
- Anastomotic leak 
- Mortality (90 days) 
- Treatment failure (1. year mortality) 
Pathology - Signet 
- Adenocarcinoma type 
- Stage 
- pTNM 
- Tumor (t) 
- Lymph nodes (n) 
- Metastasis(m) 
- Resection- status (R-status) 
Chemotherapy - Neoadjuvant or Directly to surgery 
- Adjuvant 




Table 3. Non-modifiable factors 
 
Variable   Frequency (n) Percent (%) 
  Male 111 65 
 Gender Female 59 35 
 
      
  30-44 4 2 
  45-59 24 14 
 Age 60-74 83 49 
  75+ 59 35 
 
      
 Year 2007-2011 75 44 
  2012-2017 95 56 
Table 3: This table shows the variable list of non-modifiable risk factors.  
 
Table 4. Treatment related factors 
Variable   Frequency (n) Percent (%) 
 Adjuvant Yes  69 41 
  No 101 59 
        
 
    
 
 Neoadjuvant Yes  84 49 
  No 86 51 
        
 
      
  Laparotomy 101 59 
 Surgical method Laparoscopic 69 41 
        
 
      
 Type of resection Total 104 61 
  Subtotal 66 39 







Table 5.  Distribution of pathological stage between the two arms 
Stage Open (n) Minimally invasive (n) Total (n) Percent (%)  
Stage 0 1 0 1 1 
1a 13 9 22 13 
1b 18 8 26 15 
2a 17 16 33 19 
2b 17  15 32 19 
3a 15 9 24 14 
3b 9 5 14 8 
3c 2 2 4 2 
4 5 0 5 3 
CPR 4 5 9 5 
Table 5. This table shows the distribution of stage between the two arms. Complete pathological response (CPR) is defined 
as disappearance of all invasive cancer after chemotherapy. 
 
Table 6. Pathological factors 
 
Variable   Frequency (n) Percent (%) 
 
No 138 81 
 Signet Yes 32 19 
        
 
      
  Stage 0 1 1 
  1a 22 13 
  1b 26 15 
 Stage 2a 33 19 
  2b 32 19 
  3a 24 14 
  3b 14 8 
  3c 4 2 
  4 5 3 





Variable   Frequency (n) Percent (%) 
  R0 151 89 
 Resection R1 12 7 
  CPR 7 4 
        
 
      
  T1 or T2 68 40 
Tumor  T3 or T4 93 55 
  CPR 9 5 
        
 
      
  No 84 49 
 Node Yes 77 45 
  CPR 9 5 
        
 
      
  No 156 92 
 Metastasis Yes 5 3 
  CPR 9 5 
        
Table 6. Complete pathological response (CPR) is defined as disappearance of all invasive cancer after chemotherapy. 
 
Table 7. Complications 
  
Variable     Frequency (n) Percent (%) 
 Anastomotic leak   No 154 91 
    Yes 16 9 
          
 
        
    CD > 3 128 75 
 Significant 
complication   CD ≥ 3a 42 25 





Variable     Frequency (n) Percent (%) 
    Yes 139 82 
 Alive after one year   No 31 18 
          
 
      
 90-day mortality   2007-2011 5 7 
    2012-2017 2 2 
Table 7. Clavien-dindo (CD) is a system of determining post-operative complication from I to V 
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